Therefore, targeting FAP might present a potential pleiotropic antitumor strategy for epithelial ovarian cancer, as a high expression of FAP in CAFs has proven to influence proliferation, invasion, therapy resistance, shorter recurrence, and poor clinical outcome [29–32]. This evidence concerns the gene FAP and ovarian carcinoma.